Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Retained Earnings (2021 - 2025)

Senti Biosciences has reported Retained Earnings over the past 5 years, most recently at -$358.6 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$358.6 million for Q4 2025, down 20.69% from a year ago — trailing twelve months through Dec 2025 was -$358.6 million (down 20.69% YoY), and the annual figure for FY2025 was -$358.6 million, down 20.69%.
  • Retained Earnings for Q4 2025 was -$358.6 million at Senti Biosciences, down from -$344.1 million in the prior quarter.
  • Over the last five years, Retained Earnings for SNTI hit a ceiling of -$1178.0 in Q1 2021 and a floor of -$358.6 million in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$227.5 million (2023), compared with a mean of -$199.7 million.
  • Biggest five-year swings in Retained Earnings: crashed 864587.1% in 2022 and later fell 16.05% in 2025.
  • Senti Biosciences' Retained Earnings stood at -$6.5 million in 2021, then tumbled by 2558.58% to -$173.3 million in 2022, then plummeted by 41.01% to -$244.3 million in 2023, then dropped by 21.59% to -$297.1 million in 2024, then dropped by 20.69% to -$358.6 million in 2025.
  • The last three reported values for Retained Earnings were -$358.6 million (Q4 2025), -$344.1 million (Q3 2025), and -$326.0 million (Q2 2025) per Business Quant data.